旺山旺水递表港交所 独家保荐人为中信证券

Core Viewpoint - Wangshan Wangshui has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the exclusive sponsor [1] Company Overview - Wangshan Wangshui is a biopharmaceutical company focused on the discovery, acquisition, development, and commercialization of small molecule drugs [1] - The company's core therapeutic areas include viral infections, neuropsychiatric disorders, and reproductive health [1] - The pipeline consists of nine innovative assets, with VV116, LV232, and TPN171 being the core products targeting respective markets [1] Market Potential - The market for antiviral drugs, neuropsychiatric drugs, and reproductive health drugs in China is expected to experience significant growth in the coming years [1] Pipeline Status - Two assets in the pipeline are close to commercialization, four are in clinical stages, and three are in preclinical stages [1] Customer Base - The customer base includes licensing clients, direct sales clients, distributors, and pharmaceutical companies providing CRO services, with five major clients contributing a significant portion of revenue [1] Commercialization Model - The commercialization model includes sales through distributors and direct sales of VV116 and TPN171 to clients in Uzbekistan [1] Production Facility - Wangshan Wangshui has a GMP-certified production facility in Lianyungang, which is set to commence production in June 2024, with a designed capacity of 100 million capsules and 600 million tablets per year [1]